Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02993146 · ClinicalTrials.gov registry record · Phase 1

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

A Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
11
Enrollment target
14
Study locations

NCT02993146: Active Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI).

NCT02993146 is a Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 11 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02993146, a Phase 1 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
11 participants
Enrollment target
14
Study locations

Study Summary

This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.

Primary Outcome

Dose limiting toxicities are protocol-defined, treatment-related adverse events.

Conditions Studied

Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm Metastatic Malignant Neoplasm in the Brain

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • OTHER Pharmacological Study
  • RADIATION Whole-Brain Radiotherapy
  • DRUG Ropidoxuridine

Study Locations (14)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor
  • Wayne State University/Karmanos Cancer Institute - Detroit
  • Weisberg Cancer Treatment Center - Farmington Hills

Texas

  • UT Southwestern/Simmons Cancer Center-Dallas - Dallas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
  • Ben Taub General Hospital - Houston

California

  • UC San Diego Moores Cancer Center - La Jolla
  • University of California Davis Comprehensive Cancer Center - Sacramento

Iowa

  • University of Iowa/Holden Comprehensive Cancer Center - Iowa City

Maryland

  • University of Maryland/Greenebaum Cancer Center - Baltimore

Nebraska

  • University of Nebraska Medical Center - Omaha

New York

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2017-05-08
Est. Completion 2026-10-03
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02993146 still lists

NCT02993146 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT02993146 lists 14 locations in 9 states (Michigan, Texas, California).

Frequently Asked Questions

What is clinical trial NCT02993146 about?

NCT02993146 is a clinical study titled "Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases". This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cell...

What is the current status of trial NCT02993146?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-05-08. Estimated completion is 2026-10-03.

What conditions does trial NCT02993146 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Neoplasm in the Brain.

What interventions are being tested in trial NCT02993146?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Whole-Brain Radiotherapy (RADIATION), Ropidoxuridine (DRUG).

Who is sponsoring clinical trial NCT02993146?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02993146 being conducted?

This trial has 14 study locations across California, Iowa, Maryland, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02993146's enrollment target sits among peer trials

11 169th of 176 higher than 8 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02993146, the US trial registry maintained by the National Library of Medicine. NCT02993146 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.